Mogharrabi Marzieh, Rahimi Hamid Reza, Hasanzadeh Shima, Dastani Mostafa, Kazemi-Oskuee Reza, Akhlaghi Saeed, Soukhtanloo Mohammad
Associate Professor, Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Assistant Professor, Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
ARYA Atheroscler. 2020 May;16(3):136-145. doi: 10.22122/arya.v16i3.1938.
Coronary artery disease (CAD) is the most common type of cardiovascular disease. Increasing the expression and activity of matrix metalloproteinases (MMPs) facilitates vascular remodeling and cardiovascular complications. Curcumin (the active ingredient of turmeric) is a potent natural anti-inflammatory agent, with cardiovascular protective effects. The present study was a clinical trial for investigating the effects of curcumin on activity and gene expression of MMP-2 and MMP-9 in patients with CAD.
In this study, 70 patients with CAD (with 40%-50% stenosis) were randomly divided into two groups of curcumin (80 mg nanomicelle per day) and placebo. The intervention lasted 3 months. The activity levels of MMP-2 and MMP-9 in serum samples of patients were measured using gelatin zymography assay before and after the intervention. MMP-2 and MMP-9 gene expression in peripheral blood mononuclear cells (PBMCs) was also analyzed using real-time polymerase chain reaction (PCR). Statistical significance was set at P < 0.0500.
After 3 months of medication, the expression of MMP-9 produced by PBMCs significantly decreased in the curcumin group (0.811 ± 0.25) in comparison with the placebo group (2.23 ± 0.94) (P < 0.0001). Furthermore, the zymographic analysis showed that the administration of curcumin significantly inhibited the activity levels of MMP-2 (12469.7 ± 5308.64 pixels) and MMP-9 (14007.2 ± 5371.67 pixels) in comparison with that in patients receiving placebo (MMP-2: 17613.8 ± 5250.68 pixels; MMP-9: 20010.1 ± 3259.37 pixels) (P < 0.0500).
Our results show that curcumin can significantly reduce the expression and activity of MMP-2 and MMP-9. Because of the anti-inflammatory effects of curcumin, this compound can be considered as a new strategy for the prevention of cardiovascular events.
冠状动脉疾病(CAD)是最常见的心血管疾病类型。增加基质金属蛋白酶(MMPs)的表达和活性会促进血管重塑和心血管并发症。姜黄素(姜黄的活性成分)是一种有效的天然抗炎剂,具有心血管保护作用。本研究是一项临床试验,旨在调查姜黄素对CAD患者MMP - 2和MMP - 9活性及基因表达的影响。
在本研究中,70例CAD(狭窄程度为40% - 50%)患者被随机分为姜黄素组(每天80毫克纳米胶束)和安慰剂组。干预持续3个月。在干预前后,使用明胶酶谱法测量患者血清样本中MMP - 2和MMP - 9的活性水平。还使用实时聚合酶链反应(PCR)分析外周血单个核细胞(PBMCs)中MMP - 2和MMP - 9的基因表达。统计学显著性设定为P < 0.0500。
用药3个月后,与安慰剂组(2.23 ± 0.94)相比,姜黄素组PBMCs产生的MMP - 9表达显著降低(0.811 ± 0.25)(P < 0.0001)。此外,酶谱分析表明,与接受安慰剂的患者相比,给予姜黄素显著抑制了MMP - 2(12469.7 ± 5308.64像素)和MMP - 9(14007.2 ± 5371.67像素)的活性水平(接受安慰剂患者的MMP - 2:17613.8 ± 5250.68像素;MMP - 9:20010.1 ± 3259.37像素)(P < 0.0500)。
我们的结果表明,姜黄素可显著降低MMP - 2和MMP - 9的表达及活性。由于姜黄素的抗炎作用,该化合物可被视为预防心血管事件的一种新策略。